| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.81% | 52.07% | 49.17% | 51.54% | 53.53% | 52.23% | 53.60% | 48.85% | 40.98% | 28.00% | 36.49% | 30.67% |
| Operating Margin | -18.45% | -10.54% | -31.19% | -11.59% | 3.22% | -1.60% | -4.62% | -24.27% | -58.50% | -92.64% | -94.72% | -152.17% |
| EBITDA Margin | -16.71% | -8.78% | -29.09% | -9.80% | 5.19% | 0.50% | -2.94% | -21.11% | -52.12% | -86.13% | -88.09% | -143.35% |
| Net Margin | -20.17% | -10.21% | -29.77% | -11.81% | 2.21% | -6.89% | -6.83% | -66.68% | -67.87% | -99.05% | -99.41% | -159.94% |
| Current Ratio | 2.55 | 2.93 | 3.83 | 5.14 | 6.15 | 6.14 | 2.78 | 2.83 | 1.78 | 2.93 | 4.03 | 5.02 |
| Quick Ratio | 2.02 | 2.33 | 3.02 | 4.47 | 5.63 | 5.52 | 2.28 | 2.53 | 1.03 | 2.25 | 3.37 | 4.36 |
| Debt / Equity | 2.00 | 1.33 | 0.91 | — | — | — | — | — | -2.84 | -13.68 | 0.48 | 0.55 |
| ROE | -131.93% | -36.50% | -70.98% | -21.50% | 3.59% | -9.39% | -12.70% | -93.40% | 250.56% | 1407.91% | -114.10% | -145.72% |
| ROA | -23.23% | -9.92% | -23.37% | -8.99% | 1.72% | -4.80% | -7.59% | -59.44% | -76.60% | -74.25% | -57.88% | -74.70% |
| Asset Turnover | 1.15 | 0.97 | 0.78 | 0.76 | 0.78 | 0.70 | 1.11 | 0.89 | 1.13 | 0.75 | 0.58 | 0.47 |
| Book Value / Share | 2.31 | 4.02 | 4.83 | 6.86 | 6.73 | 6.01 | 3.33 | 2.73 | -5.13 | -0.19 | 2.19 | 2.34 |
Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.